LacNAc-VC-PAB-MMAE

Cat. No.: HY-176559 Purity: 95.02%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

LacNAc-VC-PAB-MMAE is a component of an Antibody-Drug Conjugate (ADC). LacNAc-VC-PAB-MMAE is assembled onto the N-glycosylation site of Trastuzumab (HY-P9907) by WT Endo-S2.

For research use only. We do not sell to patients.

LacNAc-VC-PAB-MMAE Chemical Structure

CAS No. : 2823367-88-8

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Drug-Linker Conjugates for ADC Isoform Specific Products:

View All Isoforms

Auristatin Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents Dual payloads

Biological Activity
Purity & Documentation
References
Customer Review

Description

LacNAc-VC-PAB-MMAE is a component of an Antibody-Drug Conjugate (ADC). LacNAc-VC-PAB-MMAE is assembled onto the N-glycosylation site of Trastuzumab (HY-P9907) by WT Endo-S2^[1].

In Vitro

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

1541.78

Formula

C₇₄H₁₁₆N₁₂O₂₃

CAS No.

2823367-88-8

Appearance

Solid

Color

White to off-white

SMILES

O=C(CO/N=C/[C@H]1O[C@H]([C@@H]([C@H]([C@H]1O)O)O)O[C@H]2[C@@H]([C@H]3N=C(O[C@H]3O[C@@H]2CO)C)O)N[C@H](C(N[C@@H](CCCNC(N)=O)C(NC4=CC=C(COC(N(C)[C@H](C(N[C@H](C(N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(N5CCC[C@H]5[C@@H]([C@H](C(N[C@@H]([C@@H](O)C6=CC=CC=C6)C)=O)C)OC)=O)=O)C(C)C)=O)C(C)C)=O)C=C4)=O)=O)C(C)C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (32.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.6486 mL	3.2430 mL	6.4860 mL
5 mM	0.1297 mL	0.6486 mL	1.2972 mL
10 mM	0.0649 mL	0.3243 mL	0.6486 mL

View the Complete Stock Solution Preparation Table

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 95.02%

Select Batch:

Data Sheet (271 KB) SDS (252 KB)

COA (251 KB) HNMR (341 KB) RP-HPLC (228 KB) LCMS (117 KB)

Handling Instructions (2659 KB)

References

[1]. Wei Shi, et al. One-step synthesis of site-specific antibody–drug conjugates by reprograming IgG glycoengineering with LacNAc-based substrates. Acta Pharm Sin B. 2021 Dec 24;12(5):2417–2428. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	0.6486 mL	3.2430 mL	6.4860 mL	16.2150 mL
	5 mM	0.1297 mL	0.6486 mL	1.2972 mL	3.2430 mL
	10 mM	0.0649 mL	0.3243 mL	0.6486 mL	1.6215 mL
	15 mM	0.0432 mL	0.2162 mL	0.4324 mL	1.0810 mL
	20 mM	0.0324 mL	0.1622 mL	0.3243 mL	0.8108 mL
	25 mM	0.0259 mL	0.1297 mL	0.2594 mL	0.6486 mL
	30 mM	0.0216 mL	0.1081 mL	0.2162 mL	0.5405 mL